8 news items
Nurix Therapeutics Upcoming Oral Presentation Of Data From Ongoing Clinical Trial Of NX-5948, A Selective BTK Degrader, At EHA2024 June 13 - 16, 2024, In Madrid, Spain
NRIX
14 May 24
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening
Nurix Therapeutics Reports First Clinical Evidence Of CNS Activity Of NX-5948, Orally Available, BTK Degrader In Development For B Cell Malignancies
NRIX
9 Apr 24
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX
9 Apr 24
studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
NRIX
2 Apr 24
or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
NRIX
25 Mar 24
in response to new information, future events, or otherwise, except as required by applicable law. Contacts
hk1uatd9aadvcza2d75yttmahm56giwkzpejdxehp2ltt1d8ak9k7
NRIX
20 Mar 24
immune responses and potentially improve outcomes in patients with solid tumors and hematologic malignancies. About Nurix
hhpx3dbeiw7 ssxwml38j78hwps3rcx1kxwpy36k2pjimyyc6
NRIX
11 Mar 24
' their stance, it signifies their response to recent developments related to Nurix Therapeutics. This offers insight into analysts' perspectives
x2f5gtwn8acuhgwtsl3gc
NRIX
11 Mar 24
of non-Hodgkin's lymphoma (NHL) including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) where durable complete responses have
- Prev
- 1
- Next